TrialBMC nephrology2014

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.

Luis Ruilope et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.